ZONHONBIO provides Allergen Immunotherapy (AIT) for the treatment of allergic diseases. AIT aims to induce tolerance and modify the natural course of allergic diseases, resulting in sustained improvement of patients' condition. It is the only causative treatment method that can alter disease progression and potentially prevent disease exacerbations.

Through our genetic engineering and recombinant technology platform, we have established standardized recombinant allergen production and developed desensitization drugs and allergen diagnostic reagents with independent intellectual property rights. Our research and development pipeline includes the treatment of common allergies such as allergic rhinitis, conjunctivitis, allergic asthma, and other symptoms caused by dust mites, pollen, pets, and food, etc. By developing safe, effective, and quality-controlled allergy immunotherapy products, we aim to provide solutions for allergic patients and improve their quality of life.

• Alleviation of Allergy Symptoms

• Induction of Immune Tolerance

• Reduction in the Use of Medications  

• Long-lasting Treatment Effects